Cardiff Oncology Stock Alpha and Beta Analysis
| CRDF Stock | USD 1.60 0.02 1.27% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cardiff Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cardiff Oncology over a specified time horizon. Remember, high Cardiff Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cardiff Oncology's market risk premium analysis include:
Beta 2.57 | Alpha (0.44) | Risk 6.55 | Sharpe Ratio (0.03) | Expected Return (0.17) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Cardiff Oncology Analysis, Cardiff Oncology Valuation, Cardiff Oncology Correlation, Cardiff Oncology Hype Analysis, Cardiff Oncology Volatility, Cardiff Oncology Price History and analyze Cardiff Oncology Performance. Cardiff Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cardiff Oncology market risk premium is the additional return an investor will receive from holding Cardiff Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cardiff Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cardiff Oncology's performance over market.| α | -0.44 | β | 2.57 |
Cardiff Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cardiff Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Cardiff Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cardiff Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how Cardiff Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cardiff Oncology shares will generate the highest return on investment. By understating and applying Cardiff Oncology stock market price indicators, traders can identify Cardiff Oncology position entry and exit signals to maximize returns.
Cardiff Oncology Return and Market Media
The median price of Cardiff Oncology for the period between Mon, Nov 17, 2025 and Sun, Feb 15, 2026 is 2.34 with a coefficient of variation of 21.56. The daily time series for the period is distributed with a sample standard deviation of 0.51, arithmetic mean of 2.35, and mean deviation of 0.43. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference | 11/24/2025 |
2 | How Cardiff Oncology Inc. stock stacks up against competitors - July 2025 Selloffs Reliable Trade Execution Plans - Newser | 12/04/2025 |
3 | Cardiff Oncology to Present at Sidotis Year-End Virtual Investor Conference | 12/08/2025 |
4 | Cardiff Oncology, Inc. Given Average Rating of Hold by Brokerages - MarketBeat | 12/17/2025 |
5 | Stock Traders Purchase High Volume of Cardiff Oncology Call Options | 12/23/2025 |
6 | Analysts Offer Predictions for CRDF FY2025 Earnings - MarketBeat | 01/06/2026 |
7 | Cardiff Oncology What Storms Can We Expect In 2026 The Case For Measured Enthusiasm - Seeking Alpha | 01/13/2026 |
8 | Insider Trading | 01/27/2026 |
9 | Cardiff Oncology Valuation Check After New Onvansertib Phase 2 Data And Leadership Changes | 01/29/2026 |
About Cardiff Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cardiff or other stocks. Alpha measures the amount that position in Cardiff Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Dividend Yield | 0.006104 | 0.005799 | Price To Sales Ratio | 272.5 | 203.72 |
Cardiff Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Cardiff Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cardiff Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cardiff Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cardiff Oncology. Please utilize our Beneish M Score to check the likelihood of Cardiff Oncology's management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cardiff Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cardiff Oncology Analysis, Cardiff Oncology Valuation, Cardiff Oncology Correlation, Cardiff Oncology Hype Analysis, Cardiff Oncology Volatility, Cardiff Oncology Price History and analyze Cardiff Oncology Performance. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Cardiff Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.